The startup specializes in the development of native IgG-like bispecific antibodies for drug discovery in immuno-oncology, enhancing their drug-like properties to improve therapeutic efficacy. This approach enables faster access to novel treatments for patients facing cancer, addressing the slow progression of drug development in this critical area.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of effective immuno-oncology drugs is often hindered by challenges in creating bispecific antibodies with desirable drug-like properties and manufacturability, leading to slow progress in delivering novel cancer treatments. Traditional approaches may also carry the risk of cytokine release syndrome (CRS) and other toxicities.
Solution
Phanes Therapeutics develops native IgG-like bispecific antibodies for immuno-oncology drug discovery, utilizing three technology platforms to enhance drug-like properties and improve therapeutic efficacy. The PACbody® platform constructs bispecific antibodies with native IgG-like structures and favorable CMC characteristics, designed for conventional manufacturing processes. The SPECpair® platform enables enhanced manufacturability of native IgG-like bispecific antibodies. The ATACCbody® platform creates conjugated IgG-like bispecific antibodies with activities modulated by their environment, designed to target solid tumors with reduced risk of CRS. These platforms facilitate the creation of bispecific antibodies with various biological targeting mechanisms.
Target Audience
Phanes Therapeutics primarily targets biopharmaceutical companies and research institutions engaged in drug discovery, research, and development, seeking to leverage advanced bispecific antibody technologies for immuno-oncology.
Features
- PACbody® platform for constructing native IgG-like bispecific antibodies with drug-like properties and conventional manufacturability.
- SPECpair® platform for enhanced manufacturability of bispecific antibodies using traditional monoclonal antibody manufacturing steps.
- ATACCbody® platform for creating bispecific antibodies with activities modulated by the environment, targeting solid tumors with reduced CRS risk.
- Service offerings include bispecific antibody design, screening, and customization for developability.
- Analytical tools and customized upstream and downstream processes for each lead molecule.
- Deliverables include lead molecules, analytical methods, and research cell bank for manufacturing.